問卷

TPIDB > Search Result

Search Result

篩選

List

326Cases

2020-12-14 - 2024-03-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2020-12-21 - 2023-12-31

Phase I

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2020-12-25 - 2026-12-31

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2021-01-01 - 2024-12-31

Phase I

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2021-03-17 - 2028-12-31

Phase III

Active
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2021-05-31 - 2026-09-30

Phase III

Completed
-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2021-07-01 - 2022-08-31

Phase I/II

-
  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2018-12-06 - 2026-03-31

Phase II

Active
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients with Advanced Neuroendocrine Tumors
  • Condition/Disease

    Neuroendocrine Tumors Pancreatic Neuroendocrine Tumor Gastro-enteropancreatic Neuroendocrine Tumor Lung Neuroendocrine Neoplasm Neuroendocrine Carcinoma

  • Test Drug

    CVM-1118 Capsules

Participate Sites
8Sites

Recruiting3Sites

Terminated4Sites

2018-06-26 - 2030-12-31

Phase II

Active
A Phase 2 Open-Label Study of the Efficacy of Venetoclax in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia in the Presence of 17p Deletion
  • Condition/Disease

    Chronic Lymphocytic Leukemia (CLL) Small Lymphocytic Lymphoma (SLL)

  • Test Drug

    Venetoclax

Participate Sites
7Sites

Recruiting6Sites